Quantum Biopharma Ltd. QNTM
3.85
(0.15)
(3.75%)
as of 25 Sep
- Market cap
- $30.9M
- P/E
- 0.0×
Follow QNTM
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
P/S ratio |
— | — | 0.00 | 165.48 | — | — | — | — | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
P/Operating CF |
— | — | 0.00 | (13.14) | — | — | — | — | — | — |
P/B ratio |
— | — | 0.00 | 1.06 | — | — | — | — | — | — |
Price to Tangible BV |
— | — | 0.00 | 1.97 | — | — | — | — | — | — |
EV/Sales |
— | — | 0.00 | 139.74 | — | — | — | — | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
EV/Operating CF |
— | — | 0.00 | (2.36) | — | — | — | — | — | — |
EV/FCF |
— | — | 0.00 | (2.29) | — | — | — | — | — | — |
Quick Ratio |
0.18 | 4.05 | 12.68 | 1.10 | 3.17 | 4.13 | 2.22 | 2.39 | 1.78 | 0.79 |
Current Ratio |
0.24 | 4.26 | 12.94 | 1.25 | 4.82 | 5.28 | 2.28 | 2.43 | 1.80 | 1.07 |
Net Debt/EBITDA |
0.17 | 1.36 | 0.65 | 0.29 | 0.65 | 1.19 | 0.74 | 0.17 | 0.52 | 0.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.42 | 0.04 | 0.81 | 0.35 | 0.60 | 0.59 | 1.20 | 0.60 | 0.48 | 0.31 |
Capex/Depreciation |
— | — | (22.02) | (0.36) | 0.00 | (0.12) | (0.08) | 0.00 | (2.04) | (5.74) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (2.76%) | (54.91%) | (67.67%) | (103.45%) | (87.62%) | (78.03%) | (55.76%) | (82.40%) | (121.65%) | (336.82%) | |
| (2.46%) | (998.87%) | (86.06%) | (93.24%) | (74.66%) | (67.25%) | (46.57%) | (64.07%) | (82.11%) | (185.11%) | |
ROIC |
0.00% | 0.00% | (68.52%) | (46.36%) | (102.12%) | (112.70%) | (126.63%) | (158.24%) | (423.62%) | (1,823.10%) |
Return on Tangible Assets |
(41.67%) | (28.39%) | (68.89%) | (368.85%) | (149.39%) | (94.23%) | (233.14%) | (270.95%) | (260.57%) | (5,373.70%) |
Average Days of Receivables |
0.00 | 0.00 | 4,039.51 | 2,934.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 12,561.75% | 10,578.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.39 | 0.32 | 0.26 | 0.31 | 0.31 | 0.29 | 0.40 |
Share Based Compensation of Revenue |
— | — | 7,253.72% | 6,237.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | 0.00 | 0.04 | — | — | — | — | — | — |
Graham Number |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Earnings Yield |
— | — | (8.14%) | (96.26%) | — | — | — | — | — | — |
Free Cash Flow Yield |
— | — | 0.00% | (36.80%) | — | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 1.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.01) | (0.03) | (0.78) | (126.15) | (103.13) | (38.55) | (47.50) | (17.78) | (6.05) | (2.51) |
Capex per Share |
0.00 | 0.00 | (0.17) | (6.40) | 0.00 | (0.93) | (0.61) | 0.00 | (0.88) | (0.95) |
Free Cash Flow per Share |
(0.01) | (0.03) | (0.95) | (132.55) | (103.13) | (39.48) | (48.11) | (17.78) | (6.93) | (3.46) |
Cash per Share |
0.01 | 0.90 | 0.89 | 54.90 | 94.47 | 65.81 | 28.51 | 5.77 | 7.09 | 1.39 |
Shareholders Equity per Share |
0.08 | 2.32 | 2.15 | 333.74 | 195.73 | 100.58 | 51.20 | 21.20 | 9.18 | 1.55 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.08 | 2.32 | 2.15 | 333.74 | 195.73 | 100.58 | 51.20 | 21.20 | 9.18 | 1.55 |
Free Cash Flow |
(0.07) | (0.15) | (17.38) | (14.41) | (19.13) | (21.25) | (28.70) | (10.83) | (7.88) | (11.37) |
Working Capital |
(0.21) | 4.12 | 16.07 | 1.73 | 21.29 | 37.23 | 10.02 | 6.52 | 5.37 | 0.42 |
Capital Expenditures |
— | (7.65) | (3.11) | (0.70) | — | (0.50) | (0.36) | — | (1.00) | (3.13) |
Net Current Asset Value |
(0.21) | 4.12 | 16.07 | 1.62 | 21.21 | 37.10 | 9.98 | 6.52 | 5.37 | 0.42 |
EV/EBIT |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Capex to Sales |
— | — | 45.42 | 3.59 | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | (25,578.54%) | (20,201.08%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.02 | 0.22 | 0.00 | 19.03 | 42.90 | 28.61 | 6.38 | 8.15 |
Cash ROIC |
(156.97%) | (48.98%) | (42.45%) | (53.48%) | (35.54%) | (23.40%) | (59.81%) | (66.46%) | (37.59%) | (85.78%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.13 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Average Receivables |
0.17 | 0.17 | 0.53 | 1.16 | 0.86 | 0.33 | 0.44 | 3.90 | 5.61 | 2.02 |
Average Payables |
— | — | 2.85 | 2.35 | 3.53 | 5.61 | 7.31 | 5.65 | 4.28 | 4.27 |
Average Inventory |
— | — | — | — | — | — | — | — | 0.41 | 0.08 |
Average Assets |
7.19 | 0.35 | 20.36 | 41.97 | 42.59 | 52.47 | 50.69 | 27.94 | 17.30 | 14.14 |
Average Common Equity |
6.42 | 6.42 | 25.89 | 37.82 | 36.29 | 45.22 | 42.34 | 21.73 | 11.67 | 7.77 |
Columns are period end dates